Osteoarthritis (OA) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

News provided by

Jan 10, 2012, 03:57 ET

NEW YORK, Jan. 10, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Osteoarthritis (OA) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
http://www.reportlinker.com/p0490272/Osteoarthritis-OA-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Osteoarthritis (OA) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Osteoarthritis (OA) Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global osteoarthritis therapeutics market. The report identifies the key trends shaping and driving the global osteoarthritis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global osteoarthritis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimates that the global OA therapeutics market was worth $4.4 billion in 2010 and forecasts it to grow at a compound annual growth rate (CAGR) of 3.8% to reach $5.9 billion by 2018. The current treatment options for OA offer only symptomatic relief and are primarily dominated by generics. There are no disease modifying osteoarthritis drugs (DMOAD) currently approved in the OA therapeutics market and the late stage pipeline also lacks DMOADs except SMC021. Owing to all the above factors the OA therapeutics market is expected to show slow growth till 2018.

Scope

The report provides information on the key drivers and challenges of the osteoarthritis therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) osteoarthritis therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing analysis of the different phases of development, mechanisms of action and emerging trends. Pipeline candidates for osteoarthritis fall under major therapeutic classes such as stem cell therapy, cyclooxygenase (COX) inhibitor, cathepsin inhibitors, opioid receptor agonist, anti-nerve growth factor (NGF) inhibitor, transient receptor potential vanilloid-1 (TRPV-1) antagonists, cyclooxygenase inhibiting nitric oxide donor, phosphodiesterase inhibitor and calcitonin receptor agonist.
- Analysis of current and future competition in the global osteoarthritis market is provided. Key market players covered are BioDelivery Sciences International, Cephalon Inc, Iroko Pharmaceuticals, LLC, Novartis AG, SantoSolve AS and Winston Pharmaceuticals, Inc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the osteoarthritis therapeutics market.
- Analysis of key recent licensing and partnership agreements in osteoarthritis therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global osteoarthritis therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global osteoarthritis therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global osteoarthritis therapeutics market landscape? – Identify, understand and capitalize.

1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Osteoarthritis Therapeutics - Introduction 7
2.1 Overview 7
2.2 Epidemiology 7
2.3 Etiology and Pathophysiology 8
2.4 Risk Factors 9
2.5 Symptoms 10
2.6 Diagnosis of OA 10
2.6.1 Clinical History 10
2.6.2 Physical Examination 10
2.6.3 Diagnostic Imaging Techniques 11
2.7 Treatment 11
2.7.1 Non-Pharmacological Therapy 12
2.7.2 Pharmacological Therapy 12
2.7.3 Surgical Treatment 13
2.8 GlobalData Pipeline Report Guidance 14
3 Osteoarthritis Therapeutics - Market Characterization 15
3.1 Major Markets, Market Size (2005-2010) 15
3.2 Major Markets, Market Forecast (2010-2018) 17
3.3 OA Therapeutics Market Size (2005-2010) - The US 19
3.4 OA Therapeutics Market Forecast (2010-2018) - The US 20
3.5 OA Therapeutics Market Size (2005-2010) - The UK 21
3.6 OA Therapeutics Market Forecast (2010-2018) - The UK 22
3.7 OA Therapeutics Market Size (2005-2010) - France 23
3.8 OA Therapeutics Market Forecast (2010-2018) - France 24
3.9 OA Therapeutics Market Size (2005-2010) - Germany 25
3.10 OA Therapeutics Market Forecast (2010-2018) - Germany 26
3.11 OA Therapeutics Market Size (2005-2010) - Italy 27
3.12 OA Therapeutics Market Forecast (2010-2018) - Italy 28
3.13 OA Therapeutics Market Size (2005-2010) - Spain 29
3.14 OA Therapeutics Market Forecast (2010-2018) - Spain 30
3.15 OA Therapeutics Market Size (2005-2010) - Japan 31
3.16 OA Therapeutics Market Forecast (2010-2018) - Japan 32
3.17 Drivers and Barriers for the OA Therapeutics Market 33
3.17.1 Drivers for the OA Therapeutics Market 33
3.17.2 Barriers for the OA Therapeutics Market 33
3.18 Key Events Impacting the Future Market 34
3.19 Opportunity and Unmet Need 35
3.20 Key Takeaway 35
4 OA Therapeutics Market - Competitive Assessment 36
4.1 Overview 36
4.1.1 Strategic Competitor Assessment 36
4.2 Profiles of Commonly Used Products in the OA Therapeutics Market 37
4.2.1 5.2.1 Celebrex (celecoxib) 37
4.2.2 Cymbalta (duloxetine hydrochloride) 37
4.2.3 Hyalgan (sodium hyaluronate) 38
4.2.4 Nucynta (tapentadol) 39
4.2.5 Voltaren Gel (diclofenac sodium topical gel 1%) 40
4.3 Key Takeaway 40
5 OA Therapeutics Market - Pipeline Assessment 41
5.1 Overview 41
5.2 Strategic Pipeline Assessment 41
5.2.1 OA Therapeutics - Molecules in Pre-Registration 43
5.2.2 OA Therapeutics - Phase III Pipeline 43
5.2.3 OA Therapeutics - Phase II/III Pipeline 43
5.2.4 OA Therapeutics - Phase II Pipeline 43
5.2.5 OA Therapeutics - Phase I/II Pipeline 44
5.2.6 OA Therapeutics - Phase I Pipeline 44
5.2.7 OA Therapeutics - Preclinical Pipeline 45
5.2.8 OA Therapeutics - Discovery Pipeline 45
5.3 OA Pipeline by Mechanism of Action 46
5.4 OA Technology Trends Analytical Framework 48
5.5 OA Therapeutics - Promising Drugs under Clinical Development 49
5.6 Molecule Profile for Promising Drugs under Clinical Development 50
5.6.1 Cartistem 50
5.6.2 Civanex (civamide, zucapsaicin) 50
5.6.3 Strontium Chloride Hexahydrate (2PX) 51
5.6.4 Oral Salmon Calcitonin (SMC021) 51
5.6.5 BEMA Buprenorphine 52
5.6.6 IP 880 and IP 889 52
5.7 Key Takeaway 52
6 Osteoarthritis Therapeutics - Clinical Trials Mapping 53
6.1 Clinical Trials by Country (US, EU5 and Japan) 53
6.2 Clinical Trials by Phase 54
6.3 Clinical Trials by Trial Status 55
6.4 Prominent Sponsors 56
6.5 Top Companies Participating in OA Therapeutics Clinical Trials 58
7 Osteoarthritis Therapeutics - Strategic Assessment 59
7.1 Osteoarthritis Therapeutics - Implications for Future Market Competition 59
8 Osteoarthritis Therapeutics - Future Players in the Market 60
8.1 Introduction 60
8.1.1 BioDelivery Sciences International 60
8.1.2 Cephalon, Inc. 61
8.1.3 Iroko Pharmaceuticals, LLC 63
8.1.4 Novartis AG 64
8.1.5 SantoSolve AS 66
8.1.6 Winston Pharmaceuticals, Inc. 66
8.1.7 Other Companies in Osteoarthritis Therapeutics Market 67
9 OA Therapeutics - Licensing and Partnership Deals 69
10 Osteoarthritis Therapeutics - Appendix 73
10.1 Definitions 73
10.2 Acronyms 73
10.3 Research Methodology 74
10.3.1 Coverage 74
10.3.2 Secondary Research 75
10.3.3 Forecasting 75
10.3.4 Primary Research 78
10.3.5 Expert Panel Validation 78
10.4 Contact Us 78
10.5 Disclaimer 78
10.6 Bibliography 79

List of Tables

Table 1: Osteoarthritis - Prevalence, Major Markets, 2010 7
Table 2: Surgical Procedures for Osteoarthritis 13
Table 3: OA Therapeutics Market, Major Markets, Revenue ($bn), 2005 - 2010 15
Table 4: OA Therapeutics Market, Major Markets, Forecast ($bn), 2010 - 2018 17
Table 5: OA Therapeutics Market, The US, Revenue ($bn), 2005 - 2010 19
Table 6: OA Therapeutics Market, The US, Forecast ($bn), 2010 - 2018 20
Table 7: OA Therapeutics Market, The UK, Revenue ($m), 2005 - 2010 21
Table 8: OA Therapeutics Market, The UK, Forecast ($m), 2010 - 2018 22
Table 9: OA Therapeutics Market, France, Revenue ($m), 2005 - 2010 23
Table 10: OA Therapeutics Market, France, Forecast ($m), 2010 - 2018 24
Table 11: OA Therapeutics Market, Germany, Revenue ($m), 2005 - 2010 25
Table 12: OA Therapeutics Market, Germany, Forecast ($m), 2010 - 2018 26
Table 13: OA Therapeutics Market, Italy, Revenue ($m), 2005 - 2010 27
Table 14: OA Therapeutics Market, Italy, Forecast ($m), 2010 - 2018 28
Table 15: OA Therapeutics Market, Spain, Revenue ($m), 2005 - 2010 29
Table 16: OA Therapeutics Market, Spain, Forecast ($m), 2010 - 2018 30
Table 17: OA Therapeutics Market, Japan, Revenue ($m), 2005 - 2010 31
Table 18: OA Therapeutics Market, Japan, Forecast ($m), 2010 - 2018 32
Table 19: OA Therapeutics - Molecules in Pre-Registration 43
Table 20: OA Therapeutics - Phase III Pipeline 43
Table 21: OA Therapeutics - Phase II/III Pipeline 43
Table 22: OA Therapeutics - Phase II Pipeline 43
Table 23: OA Therapeutics - Phase I/II Pipeline 44
Table 24: OA Therapeutics - Phase I Pipeline 44
Table 25: OA Therapeutics - Preclinical Pipeline 45
Table 26: OA Therapeutics - Discovery Pipeline 45
Table 27: Other Mechanisms of Action from Figure 29 47
Table 28: OA Therapeutics - Promising Drugs Under Clinical Development, 2011 49
Table 29: OA Therapeutics - Clinical Trials by Country, 2011 53
Table 30: OA Therapeutics - Clinical Trials by Phase, 2011 54
Table 31: OA Therapeutics - Clinical Trials by Status, 2011 55
Table 32: OA Therapeutics, Overall Sponsors, 2011 56
Table 33: OA Therapeutics - Prominent Sponsors, 2011 57
Table 34: OA Therapeutics - Top Companies Participating in Clinical Trials, 2011 58
Table 35: BioDelivery Sciences International - Osteoarthritis Therapeutics Pipeline 61
Table 36: Cephalon, Inc. - Osteoarthritis Therapeutics Pipeline 63
Table 37: Iroko Pharmaceuticals, LLC - Osteoarthritis Therapeutics Pipeline 63
Table 38: Novartis AG - Osteoarthritis Therapeutics Pipeline 65
Table 39: SantoSolve AS - Osteoarthritis Therapeutics Pipeline 66
Table 40: Winston Pharmaceuticals, Inc. - Osteoarthritis Therapeutics Pipeline 66
Table 41: OA Therapeutics Market- Future Players 67
Table 42: OA Therapeutics - Licensing and Partnership Deals 69

List of Figures

Figure 1: Aetiology and Pathophysiology of Osteoarthritis 8
Figure 2: Articular Structures Affected in Osteoarthritis 9
Figure 3: OA Treatment Overview 11
Figure 4: OA Therapeutics Market, Major Markets, Revenue ($bn), 2005 - 2010 15
Figure 5: OA Therapeutics, Market Share ($m), 2010 16
Figure 6: OA Therapeutics Market, Major Markets, Forecast ($bn), 2010 - 2018 17
Figure 7: OA Therapeutics, Market Share ($m), 2018 18
Figure 8: OA Therapeutics Market, The US, Revenue ($bn), 2005 - 2010 19
Figure 9: OA Therapeutics Market, The US, Forecast ($bn), 2010 - 2018 20
Figure 10: OA Therapeutics Market, The UK, Revenue ($m), 2005 - 2010 21
Figure 11: OA Therapeutics Market, The UK, Forecast ($m), 2010 - 2018 22
Figure 12: OA Therapeutics Market, France, Revenue ($m), 2005 - 2010 23
Figure 13: OA Therapeutics Market, France, Forecast ($m), 2010 - 2018 24
Figure 14: OA Therapeutics Market, Germany, Revenue ($m), 2005 - 2010 25
Figure 15: OA Therapeutics Market, Germany, Forecast ($m), 2010 - 2018 26
Figure 16: OA Therapeutics Market, Italy, Revenue ($m), 2005 - 2010 27
Figure 17: OA Therapeutics Market, Italy, Forecast ($m), 2010 - 2018 28
Figure 18: OA Therapeutics Market, Spain, Revenue ($m), 2005 - 2010 29
Figure 19: OA Therapeutics Market, Spain, Forecast ($m), 2010 - 2018 30
Figure 20: OA Therapeutics Market, Japan, Revenue ($m), 2005 - 2010 31
Figure 21: OA Therapeutics Market, Japan, Forecast ($m), 2010 - 2018 32
Figure 22: OA Therapeutics Market, Drivers and Restraints 2011 34
Figure 23: Opportunity and Unmet Need in the OA Therapeutics Market, 2011 35
Figure 24: OA Therapeutics - Strategic Competitor Assessment, 2011 36
Figure 25: OA Therapeutics - Pipeline by Phase of Clinical Development, 2011 42
Figure 26: OA Therapeutics Pipeline - DMOAD versus Symptomatic Relief, 2011 42
Figure 27: OA Market - Clinical Pipeline by Mechanism of Action, 2011 46
Figure 28: Technology Trends Analytical Framework of the OA Pipeline, 2011 48
Figure 29: Technology Trends Analytical Framework of the OA Pipeline - Description, 2011 49
Figure 30: OA Therapeutics - Clinical Trials by Country, 2011 53
Figure 31: OA Therapeutics - Clinical Trials by Phase, 2011 54
Figure 32: OA Therapeutics - Clinical Trials by Status, 2011 55
Figure 33: OA Therapeutics - Overall Sponsors, 2011 56
Figure 34: OA Therapeutics - Prominent Sponsors, 2011 57
Figure 35: OA Therapeutic Clinical Trial - Company Sponsors by Phase, 2011 58
Figure 36: Implications for Future Market Competition in the Osteoarthritis Therapeutics Market, 2011 59
Figure 37: OA Therapeutics Market - Clinical Pipeline by Company , 2011 60
Figure 38: GlobalData Market Forecasting Model 77

Companies mentioned
BioDelivery Sciences International
Cephalon, Inc.
Iroko Pharmaceuticals, LLC
Novartis AG
SantoSolve AS
Winston Pharmaceuticals, Inc.

To order this report:
Therapy Industry: Osteoarthritis (OA) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

More Market Research Report

Check our Industry Analysis and Insights